Skip to main navigation Skip to search Skip to main content

Updates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference

  • Fereshteh Talebi
  • , Fabiana Gregucci
  • , Jalal Ahmed
  • , Nir Ben Chetrit
  • , Brian D. Brown
  • , Timothy A. Chan
  • , Dhan Chand
  • , Julie Constanzo
  • , Sandra Demaria
  • , Dmitry I. Gabrilovich
  • , Encouse Golden
  • , Andrew Godkin
  • , Chandan Guha
  • , Gaorav P. Gupta
  • , Aisha Hasan
  • , Fernanda G. Herrera
  • , Howard Kaufman
  • , Donna Li
  • , Alan A. Melcher
  • , Sierra McDonald
  • Taha Merghoub, Arta M. Monjazeb, Sébastien Paris, Sean Pitroda, Anguraj Sadanandam, Dörthe Schaue, Laura Santambrogio, Phillippe Szapary, Julien Sage, James W. Welsh, Anna Wilkins, Kristina H. Young, Eric Wennerberg, Laurence Zitvogel, Lorenzo Galluzzi, Eric Deutsch, Silvia C. Formenti
  • Cornell University
  • Icahn School of Medicine at Mount Sinai
  • Cleveland Clinic Foundation
  • Case Western Reserve University
  • Agenus Inc
  • Institut de Recherche en Cancérologie de Montpellier
  • AstraZeneca
  • Cardiff University
  • Albert Einstein College of Medicine
  • University of North Carolina
  • Johnson & Johnson
  • Swiss Cancer Center Leman
  • University of Lausanne
  • Ankyra Therapeutics
  • University of Wisconsin-Madison
  • Royal Marsden Hospital
  • University of California at San Diego
  • Nanobiotix, France
  • University of Chicago
  • University of California at Los Angeles
  • Stanford University
  • University of Texas MD Anderson Cancer Center
  • The Oregon Clinic
  • Earle A. Chiles Research Institute
  • Université Paris-Sud

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

The annual ImmunoRad Conference has established itself as a recurrent occasion to explore the possibility of combining radiation therapy (RT) and immunotherapy (IT) for clinical cancer management. Bringing together a number of preclinical and clinical leaders in the fields of radiation oncology, immuno-oncology and IT, this annual event fosters indeed essential conversations and fruitful exchanges on how to address existing challenges to expand the therapeutic value of RT-IT combinations. The 8th edition of the ImmunoRad Conference, which has been held in October 2024 at the Weill Cornell Medical College of New York City, highlighted exciting preclinical and clinical advances at the interface between RT and IT, setting the stage for extra progress toward extended benefits for patients with an increasing variety of tumor types. Here, we critically summarize the lines of investigation that have been discussed at the occasion of the 8th Annual ImmunoRad Conference.

Original languageEnglish
Article number2507856
Pages (from-to)2507856
JournalOncoimmunology
Volume14
Issue number1
DOIs
StatePublished - 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Animals
  • Combined Modality Therapy
  • Humans
  • Immunotherapy/methods
  • Neoplasms/therapy
  • Radiotherapy/methods

Fingerprint

Dive into the research topics of 'Updates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference'. Together they form a unique fingerprint.

Cite this